{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:46Z","timestamp":1786119346030,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/cad.0000000000000072","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T04:29:32Z","timestamp":1388982572000},"page":"472-477","source":"Crossref","is-referenced-by-count":6,"title":["Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer"],"prefix":"10.1097","volume":"25","author":[{"given":"Edoardo","family":"Francini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Ida","family":"Fiaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Laera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210227","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","article-title":"Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.","volume":"10","author":"Chen","year":"2009","journal-title":"Lancet Oncol"},{"key":"R3-13-20210227","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrclinonc.2011.72","article-title":"Immunotherapy for the treatment of prostate cancer.","volume":"8","author":"Di Lorenzo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-13-20210227","first-page":"118","article-title":"Second-line chemotherapy for advanced hormone-refractory prostate cancer.","volume":"6","author":"Garmey","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"R6-13-20210227","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ctrv.2008.05.004","article-title":"The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.","volume":"34","author":"Petrioli","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R11-13-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/era.11.196","article-title":"Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.","volume":"12","author":"Bedoya","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"R16-13-20210227","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods.","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"R17-13-20210227","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3959(88)90203-5","article-title":"The Italian Pain Questionnaire.","volume":"33","author":"De Benedittis","year":"1988","journal-title":"Pain"},{"key":"R18-13-20210227","first-page":"160","article-title":"Analgesic use in home hospice cancer patients.","volume":"34","author":"McCormack","year":"1992","journal-title":"J Fam Pract"},{"key":"R23-13-20210227","first-page":"148","article-title":"Neuroendocrine differentiation in prostate cancer.","volume":"1","author":"Sun","year":"2009","journal-title":"Am J Transl Res"},{"key":"R25-13-20210227","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"R27-13-20210227","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2012.09.005","article-title":"Progress in emerging therapies for advanced prostate cancer.","volume":"39","author":"Oudard","year":"2013","journal-title":"Cancer Treat Rev"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0000000000000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:01:43Z","timestamp":1786039303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201404000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000072","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}